Asia Pacific Diltiazem Market Trends and Analysis by 2028

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Asia Pacific Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)

  • Report Code : TIPRE00025367
  • Category : Life Sciences
  • No. of Pages : 109
Buy Now

The Asia Pacific diltiazem market is expected to reach US$ 160.34 million by 2028 from US$ 67.84 million in 2021; it is estimated to grow at a CAGR of 13.1% from 2021 to 2028.



Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases (CVDs), and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.

The prevalence of cardiovascular conditions is rising across the world, especially in developing nations. In these nations, the modernized facilities reduced the physical activities of people. Also, the stress level among people is growing. The incidence of CVDs is rising in developing countries, owing to the shift in lifestyle and the other health conditions caused due to the adoption of modernized facilities, which is propelling the demand for Diltiazem. The developing nations are significantly developing their healthcare facilities and services and are heading toward technological advancements. For instance, the structural heart is at the initial stage of development in the regions such as Asia Pacific. In March 2021, Glenmark Pharma gained the final USFDA nod on diltiazem hydrochloride capsules. Glenmark Pharmaceuticals has been granted a competitive generic therapy (CGT) designation for Diltiazem Hydrochloride Extended‐Release Capsules USP, 60 mg, 90 mg, and 120 mg. With the approval, the company has become the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing. Also, Glenmark is expanding its footprint in Switzerland and other developing countries. Thus, the opportunities for the market players to enter the market with cost-effective products are higher. Therefore, the factors mentioned above would create lucrative opportunities for the growth of the diltiazem market during the forecast period. Also, the diltiazem market is characterized by various small and big companies across Asia Pacific. The market players adopt strategies such as new product launches, regional expansions, and product approvals to increase their market share. The players are investing in R&D to develop advanced technologies and gain significant revenue share. Thus, recent developments are expected to act as a future trend in the diltiazem market

COVID-19 pandemic has broadly affected economies in the Asia Pacific region. The pandemic has affected three main aspects of the global economy – production, supply chain, and firms and financial markets. The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. Recently, patients with both hypertension and obesity have been increasing in Japan at exceptionally high risk of COVID-19, and thus, they need careful observation and intensive treatment. However, it is essential to note that the therapeutic mechanism of calcium channel blockers against COVID-19 still awaits further investigation and randomized controlled clinical trials. This scenario is positively impacting the diltiazem market in Asia Pacific.

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
 

ASIA PACIFIC DILTIAZEM MARKET SEGMENTATION

By Product Type

  • Tablet
  • Capsules
  • Injection

By Application

  • Hypertension
  • Angina
  • Others

By Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Company Profiles

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark

Asia Pacific Diltiazem Report Scope

Report Attribute Details
Market size in 2021 US$ 67.84 Million
Market Size by 2028 US$ 160.34 Million
Global CAGR (2021 - 2028) 13.1%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product Type
  • Capsules
  • Injection
  • Tablets
By Application
  • Angina
  • Hypertension
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    asia-pacific-diltiazem-market-report-deliverables-img1
    asia-pacific-diltiazem-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    Asia Pacific Diltiazem Market
    Connect With Expert
    1. Bausch Health Companies Inc.
    2. Teva Pharmaceutical Industries Ltd
    3. MYLAN N.V.
    4. Pfizer Inc.
    5. Sandoz (Novartis AG)
    6. Sun Pharmaceutical Industries Ltd
    7. Hikma Pharmaceuticals PLC
    8. Zydus Cadila
    9. Glenmark
    asia-pacific-diltiazem-market-cagr